The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
10-year follow up of a phase 2 clinical trial of pembrolizumab (pembro) in microsatellite instability-high (MSI-H)/mismatch repair deficient (dMMR) advanced solid tumors.
 
Katherine Bever
Employment - AstraZeneca (I); Personal Genome Diagnostics (I); Qiagen (I); SOPHiA Genetics (I)
Stock and Other Ownership Interests - SOPHiA Genetics (I)
Research Funding - Bristol-Myers Squibb (Inst); Merck (Inst)
 
Jennifer Durham
Employment - AstraZeneca/MedImmune (I)
Stock and Other Ownership Interests - AstraZeneca/MedImmune (I)
 
Hanfei Qi
No Relationships to Disclose
 
Nilofer Azad
Stock and Other Ownership Interests - Cage Pharma; Irazu; Tempus
Consulting or Advisory Role - Agenus; Astellas Pharma; AstraZeneca; BeiGene; GlaxoSmithKline; Incyte; Jazz Pharmaceuticals; Jazz Pharmaceuticals; Lilly; Mirati Therapeutics; Taiho Pharmaceutical; Tempus
Research Funding - Agios (Inst); Array BioPharma (Inst); Astex Pharmaceuticals (Inst); AtlasMedx (Inst); Bayer (Inst); BeiGene (Inst); BeiGene (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Debiopharm Group (Inst); EMD Serono (Inst); Genentech (Inst); Incyte (Inst); Intensity Therapeutics (Inst); Loxo/Lilly (Inst); Merck (Inst); Mirati Therapeutics (Inst); Revolution Medicines (Inst); Syndax (Inst)
Travel, Accommodations, Expenses - Mirati Therapeutics
 
Dan Laheru
No Relationships to Disclose
 
George Fisher
Honoraria - echina health
Consulting or Advisory Role - AstraZeneca; Genentech/Roche; Hutchison MediPharma
Research Funding - Genentech/Roche (Inst); Merck (Inst); PEEL Therapeutics (Inst)
Travel, Accommodations, Expenses - Bristol Myers Squibb Foundation
 
Richard Goldberg
Stock and Other Ownership Interests - Advanced Chemotherapy Technologies; Compass Therapeutics; Quest Diagnostics
Consulting or Advisory Role - Abbvie; Agenus; AstraZeneca; Bayer; Compass Therapeutics; Eisai/H3 Biomedicine; Focal Medical, inc; G1 Therapeutics; GeneCentric; Haystack Oncology; Innovative Cellular Therapeutics Co; Inspira; IQvia; Merck; Modulation Therapeutics; RIN Institute; Sorrento Therapeutics; Taiho Pharmaceutical; Takeda; UpToDate; Valar Labs
Expert Testimony - Johns Hopkins Hospital; Taiho Pharmaceutical
 
Tim Greten
No Relationships to Disclose
 
John Hays
Consulting or Advisory Role - AADi; Alkermes; AstraZeneca; Clovis Oncology; Deciphera; Immunogen; Ipsen; Merck; Mersana; Mural Oncology; Tesaro
Travel, Accommodations, Expenses - AstraZeneca; Merck; Regeneron; Tesaro
 
Anuradha Krishnamurthy
No Relationships to Disclose
 
Kim Reiss
Honoraria - MJH Life Sciences
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Carisma Therapeutics; Foundation Medicine; Guardant Health; Merus NV; MOMA Therapeutics
Research Funding - Bristol-Myers Squibb (Inst); Clovis Oncology; GlaxoSmithKline (Inst); Lilly (Inst); Tesaro (Inst)
Patents, Royalties, Other Intellectual Property - Royalties from invention (I)
Expert Testimony - Elmhurst Hospital; NYU School of Medicine
 
Rachel Sanborn
Honoraria - Curio Science; Illumina; OncLive/MJH Life Sciences; Targeted Oncology
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; BeiGene; Boehringer Ingelheim; Daiichi Sankyo; G1 Therapeutics; GE Healthcare; Gilead Sciences; GlaxoSmithKline; IDEOlogy Health; Illumina; InhibRx; Janssen Oncology; Johnson & Johnson/Janssen; Lilly; OSE Immunotherapeutics; Pfizer; Sanofi/Aventis
Research Funding - AstraZeneca; Bristol-Myers Squibb (Inst); Merck
Travel, Accommodations, Expenses - Hotspot Therapeutics; Hotspot Therapeutics
 
Robert Anders
Consulting or Advisory Role - AstraZeneca/MedImmune; Bristol Myers Squibb Foundation; Daiichi Sankyo; Merck Sharp & Dohme; RAPT Therapeutics
 
Hao Wang
No Relationships to Disclose
 
Luis Diaz
Leadership - Epitope Diagnostics
Stock and Other Ownership Interests - Amgen (I); Delfi Diagnostics; Epitope Diagnostics; Neophore; Seer; Zydecom
Consulting or Advisory Role - Neophore; Seer; Zydecom
Patents, Royalties, Other Intellectual Property - EP-2912468-B1 - Papanicolaou test for ovarian and endometrial cancers; EP-3322824-A1 - Detection of tumor-derived dna in cerebrospinal fluid; US-2005202465-A1 - Thymidylate synthase gene and metastasis; US-2010041048-A1 - Circulating Mutant DNA to Assess Tumor Dynamics; US-2013323167-A1 - Detecting and treating solid tumors through selective disruption of tumor vasculature; US-2014227271-A1 - Somatic mutations in atrx in brain cancer; US-2015252415-A1 - Arid1b and neuroblastoma; US-2015344970-A1 - Personalized Tumor Biomarkers; US-2016208340-A1 - TERT Promoter Mutations in Urothelial Neoplasia; US-2016273049-A1 - Systems and methods for analyzing nucleic acid (Inst); US-2017016075-A1 - Neoantigen analysis (Inst); US-2017267760-A1 - Checkpoint Blockade and Microsatellite Instability; US-2018086832-A1 - Hla-restricted epitopes encoded by somatically mutated genes; US-2018135044-A1 - Non-unique barcodes in a genotyping assay (Inst); US-2018171413-A1 - Head and neck squamous cell carcinoma assays; US-2018171413-A1 - Head and neck squamous cell carcinoma assays; US-2018171413-A1 - Head and neck squamous cell carcinoma assays; US-2018258490-A1 - Assaying ovarian cyst fluid; US-9976184-B2 - Mutations in pancreatic neoplasms; WO-2010118016-A2 - Digital quantification of dna methylation; WO-2012094401-A2 - Genes frequently altered in pancreatic neuroendocrine tumors; WO-2018071796-A2 - Compositions and methods for identifying functional anti-tumor t cell responses
Other Relationship - Blackstone; Innovatus Capital Partners
 
Dung Le
Honoraria - Merck
Consulting or Advisory Role - AstraZeneca; Bayer; Bristol-Myers Squibb; Catenon; Endeavor BioMedicines; G1 Therapeutics; HalioDX; Janssen; Merck; Merus NV; Nouscom; Regeneron; Sirtex Medical; Tango Therapeutics; Taovtek Biotherapeutics
Research Funding - Abbvie; Abbvie (Inst); Aduro Biotech; Bristol-Myers Squibb; Curegenix; DynamiCure Biotechnology; Medivir; Merck; Nouscom (Inst)
Patents, Royalties, Other Intellectual Property - Inventor of technology, "Microsatellite Instability as a Pharmacogenomic Marker of Therapeutic Response to Immune Checkpoint Inhibition".